Symbol List Views
Stock Details
CHARTS
COMPANY NEWS
STOCK ANALYSIS
FUNDAMENTALS
HOLDINGS
Edit Symbol List
Symbol Lookup
AMGN: Stock Quote & Summary Data
0.07%
| Last Sale | |
| Change Net / % |
|
| Best Bid / Ask | |
| 1y Target Est: | $ 70.00 |
| Today's High / Low | / |
| Share Volume | |
| 50 Day Avg. Daily Volume | 6,437,678 |
| Previous Close | $ 57.46 |
| 52 Wk High / Low | $ 64.76 / $ 44.96 |
| Shares Outstanding | 1,012,138,000 |
| Market Value | $ 58,116,963,960 |
| P/E Ratio | 11.69 |
| Forward P/E (1yr) | 10.48 |
| Earnings Per Share | $ 4.91 |
| Annualized Dividend | N/A |
| Ex Dividend Date | N/A |
| Dividend Payment Date | N/A |
| Current Yield | N/A |
| Beta | 0.71 |
| NASDAQ Official Open Price: | $ 58.24 |
| Date of NASDAQ Official Open Price: | Feb. 9, 2010 |
| NASDAQ Official Close Price: | $ 57.46 |
| Date of NASDAQ Official Close Price: | Feb. 8, 2010 |
Intraday Chart |
| 5d | 1m | 6m | 12m | More Charting |
Have a Question About AMGN?
Ask your question about about Amgen Inc. (AMGN) by typing it in the box below. You'll get direct responses from other members of the NASDAQ Answers community!
Hot Topics in NASDAQ Answers
The most popular questions & answers in the
NASDAQ Answers Community:
Company Description (as filed with the SEC)
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” and “us”) was incorporated in 1980 and is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. We operate in one business segment — human therapeutics. We market human therapeutic products in the areas of supportive cancer care, nephrology, inflammation and oncology. Our principal products include Aranesp® (darbepoetin alfa), EPOGEN ® (Epoetin alfa), Neulasta® (pegfilgrastim), NEUPOGEN® (Filgrastim) and Enbrel ® (etanercept). Aranesp® and EPOGEN® stimulate the production of red blood cells to treat anemia and belong to a class of drugs referred to as erythropoiesis-stimulating agents (“ESAs”). Aranesp® is used for the treatment of anemia both in supportive cancer care and in nephrology. EPOGEN® is used to treat anemia associated with chronic renal failure (“CRF”). ... More ...
Links to all Amgen Inc. (AMGN) Pages
Stock Analysis
Fundamentals
Holdings/Ownership
Company News for AMGN |
||
|
Amgen Advances Effort To Sell Bone Drug For Cancer Patients - Dow Jones Business News 02/09/2010 1:00PM |
||
|
Don't Invest Another Penny - The Motley Fool 02/09/2010 12:41PM |
||
|
Bone Up On This Potential Blockbuster - The Motley Fool 02/09/2010 11:46AM |
||
|
Hopes Of Diffusion Of European Debt Crisis May Lead To Some Bargain Hunting - RTTNews Daily Market Analysis - RTT News 02/09/2010 9:11AM |
||
|
Amgen's Denosumab Meets Primary Goal In Delaying Bony Issues In Metastatic Prostate Cancer Patients - Update - RTT News 02/09/2010 12:04AM |
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $ 5.15 |
| Quarterly EPS Est: | $ 1.24 |
| PEG Ratio: | 1.47 |
| Mean Recommendation: View Summary/View All |
1.88 |
